Search results

Skip to results

Area of interest

Type

Status

Last updated

Showing 2221 to 2235 of 8202 results

  1. STS101 for treating acute migraine [TSID11782]

    Awaiting development [GID-TA11147] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia [TSID11977]

    Awaiting development [GID-TA11507] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular or marginal zone lymphoma after 1 or more anti-CD20 treatments [ID6413]

    Awaiting development [GID-TA11488] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation [ID6460]

    Awaiting development [GID-TA11534] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps [TSID11918]

    Awaiting development [GID-TA11429] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Abortion Care

    In development [GID-NG10433] Expected publication date: 27 May 2025

    NICE guideline
    In development

  7. Urolon, (MT821)

      Status ...

    Medical technologies guidance
    Topic selection

  8. Pegzilarginase for treating arginase-1 deficiency [ID4029]

    In development [GID-HST10054] Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  9. Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over [TSID10642]

    Awaiting development [GID-TA11308] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy ID6161

    In development [GID-TA11099] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Tislelizumab in combination for untreated advanced non-small-cell lung cancer ID6162

    In development [GID-TA11101] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Pegcetacoplan for treating geographic atrophy [ID4041]

    In development [GID-TA11351] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer PD [ID6526]

    Awaiting development [GID-TA11502] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Bimekizumab for treating ankylosing spondylitis [TSID10334]

    Awaiting development [GID-TA11150] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. AposHealth for knee osteoarthritis (MTG76)

    Evidence-based recommendations on AposHealth for knee osteoarthritis.

    Medical technologies guidance
    Published
    11 April 2023
    View recommendations

    Sections for MTG76